Potential of regulatory T-cell-based therapies in the management of severe COVID-19

In view of dysregulated immune response, “cytokine storm” and inflammation-induced lung damage in severely ill COVID-19 patients, we propose that CD4(+)CD25(+)FoxP3(+) regulatory T-cell-based therapies could be considered for patient management https://bit.ly/3eKqWPo

Detalles Bibliográficos
Autores principales: Stephen-Victor, Emmanuel, Das, Mrinmoy, Karnam, Anupama, Pitard, Bruno, Gautier, Jean-François, Bayry, Jagadeesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331657/
https://www.ncbi.nlm.nih.gov/pubmed/32616599
http://dx.doi.org/10.1183/13993003.02182-2020
_version_ 1783553376438452224
author Stephen-Victor, Emmanuel
Das, Mrinmoy
Karnam, Anupama
Pitard, Bruno
Gautier, Jean-François
Bayry, Jagadeesh
author_facet Stephen-Victor, Emmanuel
Das, Mrinmoy
Karnam, Anupama
Pitard, Bruno
Gautier, Jean-François
Bayry, Jagadeesh
author_sort Stephen-Victor, Emmanuel
collection PubMed
description In view of dysregulated immune response, “cytokine storm” and inflammation-induced lung damage in severely ill COVID-19 patients, we propose that CD4(+)CD25(+)FoxP3(+) regulatory T-cell-based therapies could be considered for patient management https://bit.ly/3eKqWPo
format Online
Article
Text
id pubmed-7331657
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-73316572020-07-10 Potential of regulatory T-cell-based therapies in the management of severe COVID-19 Stephen-Victor, Emmanuel Das, Mrinmoy Karnam, Anupama Pitard, Bruno Gautier, Jean-François Bayry, Jagadeesh Eur Respir J Agora In view of dysregulated immune response, “cytokine storm” and inflammation-induced lung damage in severely ill COVID-19 patients, we propose that CD4(+)CD25(+)FoxP3(+) regulatory T-cell-based therapies could be considered for patient management https://bit.ly/3eKqWPo European Respiratory Society 2020-09-03 /pmc/articles/PMC7331657/ /pubmed/32616599 http://dx.doi.org/10.1183/13993003.02182-2020 Text en Copyright ©ERS 2020. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Agora
Stephen-Victor, Emmanuel
Das, Mrinmoy
Karnam, Anupama
Pitard, Bruno
Gautier, Jean-François
Bayry, Jagadeesh
Potential of regulatory T-cell-based therapies in the management of severe COVID-19
title Potential of regulatory T-cell-based therapies in the management of severe COVID-19
title_full Potential of regulatory T-cell-based therapies in the management of severe COVID-19
title_fullStr Potential of regulatory T-cell-based therapies in the management of severe COVID-19
title_full_unstemmed Potential of regulatory T-cell-based therapies in the management of severe COVID-19
title_short Potential of regulatory T-cell-based therapies in the management of severe COVID-19
title_sort potential of regulatory t-cell-based therapies in the management of severe covid-19
topic Agora
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331657/
https://www.ncbi.nlm.nih.gov/pubmed/32616599
http://dx.doi.org/10.1183/13993003.02182-2020
work_keys_str_mv AT stephenvictoremmanuel potentialofregulatorytcellbasedtherapiesinthemanagementofseverecovid19
AT dasmrinmoy potentialofregulatorytcellbasedtherapiesinthemanagementofseverecovid19
AT karnamanupama potentialofregulatorytcellbasedtherapiesinthemanagementofseverecovid19
AT pitardbruno potentialofregulatorytcellbasedtherapiesinthemanagementofseverecovid19
AT gautierjeanfrancois potentialofregulatorytcellbasedtherapiesinthemanagementofseverecovid19
AT bayryjagadeesh potentialofregulatorytcellbasedtherapiesinthemanagementofseverecovid19

Ejemplares similares